Keywords: titan/bayer, schering, parkinson, candidate, did, meet, endpoint
Titan/Bayer Schering's Parkinson's candidate did not meet endpoint
Article | 07 July 2008
The USA's Titan Pharmaceuticals says that Spheramine, its novel cell-based therapy for the treatment of moderate-to-advanced Parkinson's disease developed with ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US Supreme Court says patent settlement can "sometimes" be illegal
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
- Daiichi Sankyo files for Japanese approval of Prasugrel
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
